Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

By sjmartinez • August 31, 2023

Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S92-S100. doi: 10.1093/infdis/jiad209. PMID: 37650234.

Tags: adaptive platform trials, covid-19, Harbor UCLA, Infectious Diseases, pooled placebo, Publications, randomization

Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort

Razavi AC, Chen J, Yang W, Sha D, Dzaye O, Bhatia HS, Tsimikas S, Lash JP, Kansal M, Rincon-Choles H, Vaccarino V, Jacobson TA, Budoff[...]

A Fellow-Led Orientation to Mitigate Microaggressions in the Intensive Care Unit

Rink DE, Adamson R, Granados L, Cueva KL, Albert TJ. A Fellow-Led Orientation to Mitigate Microaggressions in the Intensive Care Unit. Med Educ. 2025 Aug[...]

Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence

Chan AA, Noguti J, Ramirez NM, Navarrete M, Lee DJ. Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence. J Invest Dermatol. 2025[...]